Investments, Funding & Disinvestment

Under the agreement, the companies will advance Sail’s lead programme, SAIL-0839, which is being developed to engineer CD4+ and CD8+ T-cells inside the body to treat immune-mediated diseases.

The acquisition follows Novartis AG’s decision in 2024 to review the future of its India-listed subsidiary.

The investment will upgrade Resilience’s manufacturing operations in Ohio, where the company has produced Lilly’s Mounjaro and Zepbound since the partners began working together in 2023.

The initiative comes as scientists intensify efforts to address a major Bundibugyo ebolavirus outbreak, with cases rising rapidly in the Democratic Republic of the Congo (DRC).

Under the proposed PPP structure, the Egyptian-Turkish consortium will oversee the project’s construction and non-medical operations.

Sun Pharma disclosed the development in an exchange filing, confirming that Organon stockholders had voted in favour of the proposals required to advance the proposed merger transaction.

Under the proposed agreement, argenx will pay US$77 per share in cash to acquire all outstanding shares of Forte Biosciences.

The new facility will manufacture rapid diagnostic tests used in several areas of healthcare, including the detection of infectious diseases and epidemics, drug screening and the identification of cancer biomarkers.

Lytenava contains bevacizumab, an anti-vascular endothelial growth factor (anti-VEGF) antibody that inhibits the growth of abnormal blood vessels that can damage the retina.

Milly Glass SEZ director Mohamed Rashid said the company expects to break ground by the end of August 2026 and begin producing amber pharmaceutical bottles by July 2027.